Boston Scientific, J&J Analyses Aim To Convince CMS To Raise DES Payments

Boston Scientific and J&J are providing additional external data analyses to counter CMS' claim that more evidence is required to justify altering the drug-eluting stent diagnosis-related groups (DRGs)